Osivax

Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.